A Phase I Study of OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
University of Wisconsin, Madison
Summary
The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
Description
Stereotactic Body Radiation Therapy (SBRT) is a noninvasive local therapy with proven efficacy in a number of solid tumor types. The technique itself involves the precise administration of high biological equivalent dose radiation in order to maximize local control of discrete lesions. SBRT has been shown to be an effective therapy for both primary and metastatic liver tumors of multiple histologies. In metastatic liver disease from all primary tumor sites, patients treated with modern SBRT techniques generally enjoy very high levels of 1 and 2 year local control. However, CRC liver metastase…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Have a diagnosis of histologically confirmed or clinically suspected metastatic cancer to the liver. * Participant must be a candidate for SBRT to at least one intrahepatic lesion but no more than 6 intrahepatic lesions. * Participant must be a candidate for treatment on the ViewRay treatment unit. Must be screened to rule out implants and devices that are not MRI compatible. * Be willing and able to provide written informed consent. * Participants may be therapy-naïve or have had prior systemic therapy up to two weeks prior to study entry. * No active central nervous sy…
Interventions
- RadiationSBRT
Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments.
Location
- University of WisconsinMadison, Wisconsin